Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is a major risk factor for cardiovascular (CV) disease - the primary cause of death, worldwide. Although reducing levels of low-density lipoprotein-cholesterol can significantly reduce CV risk, a high level of residual risk persists, especially in people with obesity-related conditions, such as metabolic syndrome and type 2 diabetes mellitus. Peroxisome proliferator-activated receptor alpha- (PPARα-) agonists (e.g. fibrates), play a central role in the reduction of macro- and microvascular risk in these patients. However, the currently available fibrates are weak (PPARα-agonists) with limited efficacy due to dose-related adverse effects. To address this problem, a new generation of highly potent and selective PPARα-modulators (SPPARMα) is being developed that separate the benefits of the PPARα-agonists from their unwanted side effects. Among these, aleglitazar (a dual PPARα/γ agonist) and GFT505 (a dual PPAR α/δ agonist) have recently entered late-phase development. Although both compounds are more potent PPARα-activators than fenofibrate in vitro, only aleglitezar is more effective in lowering triglycerides and raising high-density lipoprotein-cholesterol (HDL-C) in humans. However, it is also associated with a potential risk of adverse effects. More recently, a highly potent, specific PPARα-agonist (K-877) has emerged with SPPARMα characteristics. Compared to fenofibrate, K-877 has more potent PPARα-activating efficacy in vitro, greater effects on triglycerides- and HDL-C levels in humans, and a reduced risk of adverse effects. If successful, K-877 has the potential to supersede the fibrates as the treatment of choice for patients with residual CV risk associated with metabolic syndrome and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 PPAR-agonists have the potential to trigger different biological responses via the same receptor[34].](https://figures.cochat.ai/paper-figures/09e20ee005d84d45ad8c06947dd3bfb6/selective-peroxisome-proliferator-activated-receptor-modulators-spparm-the-next-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, SPPARMα may have a better benefit-risk balance compared to the PPARα agonists such as available fibrates.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“Moreover, the risk of microvascular events in people with MetS or T2D can only be reduced by approximately 50% using the current standard of care (intensive treatment to reduce LDL-C, blood pressure and blood glucose) [5].”
BackgroundHelsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“The net effect of these actions is a significant reduction in macrovascular events in people with, but not without, atherogenic dyslipidemia [12,13,15-18], and significant reductions in T2D-related microvascular events [19-22].”
BackgroundAuthors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“Three PPAR isoforms have been identified (PPARα, γ and δ), each encoded by a separate gene [25].”
BackgroundRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“The net effect of these actions is a significant reduction in macrovascular events in people with, but not without, atherogenic dyslipidemia [12,13,15-18], and significant reductions in T2D-related microvascular events [19-22].”
BackgroundEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 6×
“fibrates) play a central role in reducing plasma concentrations of TG-rich lipoproteins, increasing HDL-C levels and reducing vascular inflammation in people with atherogenic dyslipidemia [10,12,13].”
BackgroundInfluentialMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Effects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311 · cited 4×
“The net effect of these actions is a significant reduction in macrovascular events in people with, but not without, atherogenic dyslipidemia [12,13,15-18], and significant reductions in T2D-related microvascular events [19-22].”
BackgroundInfluentialChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M.-R., Simes, R., Tse, D., Williamson, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61607-9 · Cited by 1,109
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Self-citationScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Self-citationon behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Rajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328
Roles of PPARs in NAFLD: Potential therapeutic targets
Tailleux, A., Wouters, K., & Staels, B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.016 · Cited by 282
Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance
Lewis, J. S., & Jordan, V. C. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.02.028 · Cited by 281
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Self-citationHenry, R. R., Lincoff, A. M., Mudaliar, S., Rabbia, M., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205
PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages
Neve, B. P., Corseaux, D., Chinetti, G., Zawadzki, C., Fruchart, J.-C., Duriez, P., Staels, B., & Jude, B. (2001) · Circulation · doi:10.1161/01.cir.103.2.207 · Cited by 191
Self-citationStatins and diabetes – Authors' reply
Kearney, P. M., Keech, A., Simes, J., Collins, R., & Baigent, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60761-8 · Cited by 185
Cariou, B., Zaïr, Y., Staels, B., & Bruckert, E. (2011) · Diabetes Care · doi:10.2337/dc11-0093 · Cited by 172
Higgins, L. S., & DePaoli, A. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28449e · Cited by 166
Gervois, P., Fruchart, J.-C., & Staels, B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0397 · Cited by 161
Self-citationCarey, V. J., Bishop, L. M., Laranjo, N., Harshfield, B. J., Kwiat, C., & Sacks, F. M. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.002 · Cited by 160
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism
Fruchart, J.-C., & Duriez, P. (2006) · Drugs of Today · doi:10.1358/dot.2006.42.1.963528 · Cited by 132
Self-citationPpars, metabolic disease and atherosclerosis
Fruchart, J., Staels, B., & Duriez, P. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0871 · Cited by 129
Self-citationDuez, H., Lefebvre, B., Poulain, P., Torra, I. P., Percevault, F., Luc, G., Peters, J. M., Gonzalez, F. J., Gineste, R., Helleboid, S., et al. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000154140.73570.00 · Cited by 120
Self-citationRoberts, L. D., Murray, A. J., Menassa, D. A., Ashmore, T., Nicholls, A. W., & Griffin, J. L. (2011) · Genome biology · doi:10.1186/gb-2011-12-8-r75 · Cited by 120
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 115
Yamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84 · cited 1×
“K-877 contains an acidic region similar to that found in other PPARα-agonists but, to enhance PPARα activity and selectivity, unique benzoxazole and phenoxyalkyl side-chains have been added (Figure 3) [53].”
BackgroundSelf-citationOng, K. L., Rye, K., O'Connell, R. L., Jenkins, A. J., Brown, C. S. B., Xu, A., SULLIVAN, D. R., Barter, P. J., KEECH, A. C., & on behalf of the FIELD study investigators (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2267 · Cited by 83
(1999) · PubMed · Cited by 74
Selective Modulators of PPAR Activity as New Therapeutic Tools in Metabolic Diseases
Bálint, B. L., & Nagy, L. T. (2006) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153006776056620 · Cited by 74
Rosenson, R. S., Wright, R. S., Farkouh, M. E., & Plutzky, J. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.06.023 · Cited by 69
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 66
Harano, Y., Miyawaki, T., Nabiki, J., Shibachi, M., Adachi, T., IKEDA, M., Ueda, F., & Nakano, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.173 · Cited by 58
Cantó, C., & Auwerx, J. H. (2012) · Science · doi:10.1126/science.1222646 · Cited by 57
Dietz, M., Mohr, P., Kuhn, B., Maerki, H. P., Hartman, P., Ruf, A., Benz, J., Grether, U., & Wright, M. B. (2012) · ChemMedChem · doi:10.1002/cmdc.201100598 · Cited by 47
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
Herz, M., Gaspari, F., Perico, N., Viberti, G. C., Urbanowska, T., Rabbia, M. A., & Kirk, D. A. W. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.037 · Cited by 39
Novel Peroxisome Proliferator Activated Receptor–α Agonists
Fruchart, J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.08.012 · Cited by 36
Self-citationEffect of fenofibrate treatment on type III hyperlipoproteinemia
Fruchart, J., Davignon, J., Bard, J., Grothé, A.-M., Richard, A., & Fiévet, C. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90874-6 · Cited by 30
Self-citationYounk, L. M., Uhl, L., & Davis, S. N. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.579561 · Cited by 26
[Molecular mechanism of action of the fibrates].
Fruchart, J., Duriez, P., & Staels, B. (1999) · PubMed · Cited by 23
Self-citationNúñez-Cortés, J. M., Pedro‐Botet, J., Salas, X. P., Mijares, A. H., Carey, V. J., Hermans, M. P., Sacks, F. M., & Fruchart, J. (2011) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.10.004 · Cited by 7
Self-citationNúñez-Cortés, J. M., Pedro‐Botet, J., Salas, X. P., Mijares, A. H., Carey, V. J., Hermans, M. P., Sacks, F. M., & Fruchart, J. (2011) · Endocrinología y Nutrición (English Edition) · doi:10.1016/s2173-5093(11)70035-6 · Cited by 5
Self-citation
Cited by
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Zinc status is associated with inflammation, oxidative stress, lipid, and glucose metabolism
Olechnowicz, J., Tinkov, A., Skalny, A., & Suliburska, J. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-017-0571-7 · Cited by 557
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih, M., & Jornayvaz, F. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.018 · Cited by 330
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Metadata
- Authors
- Fruchart, J.-C.
- Affiliations
- Fondation Coeur et Artères (FR)
- Corresponding author
- Fruchart, Jean-Charles
- Venue
- Cardiovascular Diabetology
- Published
- 2013
- Volume
- 12
- Issue
- 1
- Pages
- 82
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC3682868
- OpenAlex
- W2144259092
- Cited by
- 189
- References
- 54
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 18 · 2022: 10 · 2021: 15 · 2020: 18 · 2019: 15 · 2018: 22 · 2017: 16 · 2016: 13 · 2015: 11 · 2014: 17 · 2013: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα agonist, fibrates, aleglitazar, dyslipidemia, residual cardiovascular risk, metabolic syndrome, type 2 diabetes, triglycerides, HDL cholesterol, PPARα/γ dual agonist, fenofibrate, adverse effects
- MeSH terms
- Hypolipidemic Agents, Benzoxazoles, Butyrates, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Risk Factors, PPAR alpha, PPAR gamma, Dyslipidemias, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.